Compare Dyne Therapeutics Inc. Common Stock (DYN) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs iShares 10 20 Year Treasury Bond ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B), while iShares 10 20 Year Treasury Bond ETF trades at $93.76 (market cap $11.47B). The key difference: iShares 10 20 Year Treasury Bond ETF is far larger — about 4× Dyne Therapeutics Inc. Common Stock's market cap, and iShares 10 20 Year Treasury Bond ETF is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and iShares 10 20 Year Treasury Bond ETF for 62 Days on average.
| DYN | TLH | |
|---|---|---|
Market Cap | $2.86B | $11.47B |
Volume | 3,341,579 | 2,063,925 |
Sector | Health | Fixed Income |
52-Week High | $26.78 | $105.36 |
52-Week Low | $14.60 | $91.34 |
Typical Hold Time | 0 Days | 62 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
TLH, the iShares 10-20 Year Treasury Bond ETF, trades at $92.56 with a slight 0.34% daily gain amid a challenging bond market environment. Technical indicators signal a bearish trend with selling pressure outweighing buying signals. Recent trading volume spikes indicate heightened investor interest as Treasury yields reach multi-decade highs, creating volatility for long-duration bond ETFs.
The outlook remains cautious as rising interest rates pressure bond prices, though the ETF provides exposure to US Treasury securities. Key risks include continued Fed tightening and inflation concerns, while potential stabilization in yields could offer support. Institutional activity shows mixed positioning with some funds reducing exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
